Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in the peer-reviewed journal mAbs, the study presents nipocalimab's high-affinity binding to the neonatal Fc receptor (FcRn) and its capability to significantly reduce IgG levels, including harmful autoantibodies, by over 75%.
Nipocalimab is a fully human monoclonal antibody designed to selectively bind to FcRn, which plays a critical role in preserving IgG antibodies in the body. By blocking FcRn, nipocalimab aims to lower circulating IgG levels without impacting overall immune function. The drug's pH-independent binding is particularly noteworthy, as it may allow for the treatment of alloimmune diseases in pregnancy. The efficacy of nipocalimab has been supported by various preclinical studies and is consistent with outcomes from clinical trials in phases 1, 2, and 3, although its clinical significance remains to be determined.
Dr. Pushpa Narayanaswami, a neurologist at Beth Israel Deaconess Medical (TASE:PMCN) Center and Professor of Clinical Neurology at Harvard Medical School, emphasized the urgent need for targeted treatments for severe IgG-driven autoantibody diseases, such as generalized myasthenia gravis. Dr. Narayanaswami, who contributed to the research, expressed optimism about nipocalimab's unique properties in addressing these conditions' underlying causes.
Nipocalimab has received several key designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), including Fast Track designation for various conditions and Breakthrough Therapy designation for hemolytic disease of the fetus and newborn (HDFN) and Sjögren's disease. It has also been granted Orphan drug status for multiple diseases, reflecting its potential to address unmet medical needs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.